Evidence map›Paper›PMID 36612098›Full record

ArticleCancers2022

Eosin Y-Functionalized Upconverting Nanoparticles: Nanophotosensitizers and Deep Tissue Bioimaging Agents for Simultaneous Therapeutic and Diagnostic Applications.

Gabriel López-Peña, Silvia Simón-Fuente, Dirk H Ortgies, María Ángeles Moliné, Emma Martín Rodríguez, Francisco Sanz-Rodríguez, María Ribagorda

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Gabriel López-PeñaDepartamento de Física Aplicada, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049 Madrid, Spain.ORCID 0000-0001-9957-938X
Silvia Simón-FuenteDepartamento de Química Orgánica, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049 Madrid, Spain.ORCID 0000-0002-3202-9196
Dirk H OrtgiesDepartamento de Física de Materiales, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049 Madrid, Spain.ORCID 0000-0001-9693-6484
María Ángeles MolinéDepartamento de Biología, Universidad Autónoma de Madrid, C/Darwin 2, 28049 Madrid, Spain.
Emma Martín RodríguezDepartamento de Física Aplicada, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049 Madrid, Spain.ORCID 0000-0002-2190-8312
Francisco Sanz-RodríguezNanomaterials for Bioimaging Group, Instituto Ramón y Cajal de Investigación Sanitaria, 28034 Madrid, Spain.ORCID 0000-0002-9977-6102
María RibagordaDepartamento de Química Orgánica, Universidad Autónoma de Madrid, C/Francisco Tomás y Valiente 7, 28049 Madrid, Spain.ORCID 0000-0001-7185-4095
Universidad Autónoma de Madrid · ESInstituto Ramón y Cajal de Investigación Sanitaria · ES

Funding

Comunidad de Madrid S2017/BMD3867RENIMCM and SI3-PJI-2021-00211European Cooperation in Science and Technology CA17140European Union NanoTBTech (801305)Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal IMP18_38 (2018/0265)Instituto de Salud Carlos III PI19/00565MInisterio de Ciencia e Innovación PID2020-113059GB-C22Ministerio de Competitividad e Innovación MAT2016-75362-C3-1-R and PID2019-106211RB-I00Ministry of Economy, Industry and Competitiveness CTQ2017-85454-C2-2-P
6 · The paper itself

Abstract

Functionalized upconverting nanoparticles (UCNPs) are promising theragnostic nanomaterials for simultaneous therapeutic and diagnostic purposes. We present two types of non-toxic eosin Y (EY) nanoconjugates derived from UCNPs as novel nanophotosensitizers (nano-PS) and deep-tissue bioimaging agents employing light at 800 nm. This excitation wavelength ensures minimum cell damage, since the absorption of water is negligible, and increases tissue penetration, enhancing the specificity of the photodynamic treatment (PDT). These UCNPs are uniquely qualified to fulfil three important roles: as nanocarriers, as energy-transfer materials, and as contrast agents. First, the UCNPs enable the transport of EY across the cell membrane of living HeLa cells that would not be possible otherwise. This cellular internalization facilitates the use of such EY-functionalized UCNPs as nano-PS and allows the generation of reactive oxygen species (ROS) under 800 nm light inside the cell. This becomes possible due to the upconversion and energy transfer processes within the UCNPs, circumventing the excitation of EY by green light, which is incompatible with deep tissue applications. Moreover, the functionalized UCNPs present deep tissue NIR-II fluorescence under 808 nm excitation, thus demonstrating their potential as bioimaging agents in the NIR-II biological window.

Indexed as

eosin Yinfrared imagingphotodynamic therapyROSupconversion nanoparticles

Identifiers

PMID36612098
PMCPMC9817929
OpenAlexW4313247090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.